Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Joe Terranova
Regeneron Pharmaceuticals IncREGNBUYDec 22, 2023
Joe TerranovaOwned
N/A
Stock price when the opinion was issued
$608.50
As of Jun 18, 2026. Market Open.
Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
DON'T BUY
The momentum is waning, and last quarter revenue growth was only 14%. They're coming to the end of the road.
Joe TerranovaOwned
Pharma & Healthcare
HOLD
Large cap biotech. Its two franchises are dominant: macular degeneration and atopic dermatitis. One of the best at R&D. Proven ability to execute. One of the better growth profiles for next 3-5 years. Bit of volatility around reimbursement. Decent valuation. No dividend.
Paul MacDonaldOwned
Pharma & Healthcare
BUY
On Monday, they host an investors' event to showcase their work in RNA-based therapies and gene editing. Though it's a biotech, REGN is profitable and trades at a low PE. It trades on earnings and not future sales. If they tell a great story next week, he expects this stock to break out to an all-time high.
Pharma & Healthcare
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPAST TOP PICK
(A Top Pick Nov 23/20, Up 9.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with REGN has triggered its stop at $565. To remain disciplined, we recommend covering the position at this time. Combined with the previous recommendation to cover half the position, this results in a net investment gain of 15%.
Pharma & Healthcare
An analyst upgraded this to $1,025, a very long way to go. He's gained 40% in this himself. It's reasonable at a 24x PE and enjoys momentum. Sees nothing to derail this.